|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3-4
|
|
pubmed:dateCreated |
2008-9-17
|
|
pubmed:abstractText |
Gemcitabine plus UFT combination chemotherapy are highly effective and less toxic in the first line setting in patients with non-small cell lung cancer (NSCLC). The purpose of the study is to confirm the feasibility of this regimen as second- or third-line therapy in NSCLC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1349-6867
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
55
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
260-6
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18797141-Adult,
pubmed-meshheading:18797141-Aged,
pubmed-meshheading:18797141-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18797141-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18797141-Deoxycytidine,
pubmed-meshheading:18797141-Evidence-Based Medicine,
pubmed-meshheading:18797141-Female,
pubmed-meshheading:18797141-Humans,
pubmed-meshheading:18797141-Lung Neoplasms,
pubmed-meshheading:18797141-Male,
pubmed-meshheading:18797141-Middle Aged,
pubmed-meshheading:18797141-Salvage Therapy,
pubmed-meshheading:18797141-Tegafur,
pubmed-meshheading:18797141-Uracil
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Gemcitabine plus UFT combination chemotherapy as second- or third-line therapy in non-small cell lung cancer: a pilot study.
|
|
pubmed:affiliation |
Division of Pulmonary Medicine, St. Luke's International Hospital, Tokyo, Japan.
|
|
pubmed:publicationType |
Journal Article
|
